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ferent cytokines at saturated concentrations and then incubated for up to
24 hours. Lysates and supernatants were collected and intracellular and
extracellular signals were measured using a high throughput method of
bead-based ﬂuorescent readings (Luminex xMAP assay, Austin, TX). For
each treatment 18 different phosphoprotein signals was measured includ-
ing p-AKT, p-MEK, p-ERK, p-p38, p-IκB at 10 and 25 minutes post-stimuli.
At 24 hours supernatants were collected and approximately 60 different
proteins including cytokines and metalloproteinases (MMPs) were mea-
sured. Data were normalized and plotted using custom software based on
the DataRail toolbox and subsequent analysis was performed using PLSR,
PCA, and clustering algorithms that have developed previously.
Results: IL1α, IL1β, and TNFα showed a signiﬁcant release of several pro-
catabolic proteins such as MMP1 and MMP13 but also pro-inﬂammatory
cytokines such as GROα, MCP1, MIP1α, and MIP1β. Interestingly, clustering
analysis revealed a number of TLR stimuli such as LPS and POLY I:C to
behave on a similar manner. Closer look into the phosphoprotein activity of
those proteins showed they act via the NFκB and possibly via the p38 path-
ways. Follow up experiment using selective p38 and IκB inhibitors proved
the pro-catabolic response of chondrocytes triggered by TLR agonists is
NFκB dependant.
Conclusions: “Functional” screens based on intracellular and extracellular
activities revealed that chondrocytes respond to a large number of stimuli
that has not been well characterized. TLR stimuli showed a behavior similar
to IL1α and TNFα. Upon TLR stimuli, chondrocytes shows an “immune-cell”
phenotype by releasing MMPs and several pro-catabolic and inﬂammaroty
cytokines via the NFκB pathway.
Clinical Aspects and Outcomes
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Purpose: To examine comorbidities, pain-related pharmacotherapy, health
service use and direct medical costs of patients with osteoarthritis (OA) in
clinical practice.
Methods: This study was a retrospective cohort analysis based on a med-
ical and pharmacy claims database. Using the PharMetrics® Database, OA
patients (International Classiﬁcation of Diseases, Ninth Revision, Clinical
Modiﬁcation codes 715.XX) were identiﬁed and matched (age, gender, and
region) with a Control group of individuals without OA. Clinical comorbidi-
ties, pain-related pharmacotherapy, and health service use/direct medical
costs (pharmacy, outpatient, inpatient, total) were then examined during
the calendar year 2008.
Results: A total of 112,951 patients with OA satisﬁed all the study entry
criteria and were matched to 112,951 Controls without OA (mean age:
56.9±9.5 years; 62% female). Relative to Controls, OA patients were sig-
niﬁcantly more likely (p<0.0001) to have various comorbidities, including
musculoskeletal (84.3% versus 37.1%) and neuropathic pain (22.0% versus
6.1%) conditions, depression (12.4% versus 6.4%), anxiety (6.6% versus 3.5%),
and sleep disorders (11.9% versus 4.2%). OA patients were signiﬁcantly
more likely (p<0.0001) to receive pain-related medications, including opi-
oids (40.7% versus 17.1%), NSAIDs (37.1% versus 11.5%), tramadol (9.8%
versus 1.8), and prescription acetaminophen (1.3% versus 0.8%) relative to
Controls. OA patients were also signiﬁcantly more likely (p<0.0001) to be
prescribed “adjunctive” medications for treating conditions associated with
pain including depression, anxiety, and insomnia (antidepressants, 21.5%
versus 15.7%; benzodiazepines, 13.6% versus 9.1%; sedative/hypnotics, 9.6%
versus 5.3%). Use of healthcare resources including hospitalizations, emer-
gency room, physician oﬃce, and outpatient visits was signiﬁcantly higher
(p<0.0001) among OA patients relative to Controls; a majority of OA
patients (88% versus. 51% of Controls) had ≥4 physician oﬃce visits;
OA patients averaged 22 outpatient visits (versus 9 in Controls); over
13% of OA patients underwent OA-related surgeries; and 34% received
intra-articular injections during 2008. Relative to Controls, mean [SD] total
direct medical costs during 2008 were more than two times higher among
OA patients ($12,905 [$21,884] versus $5,099 [$13,855]; p < 0.001) and
median costs were more than three times higher ($6,188 versus $1,879);
p<0.0001.
Conclusions: The payer burden associated with OA was substantial,
evidenced by signiﬁcantly greater use of pain-related and adjunctive med-
ications and higher health service utilization and direct medical costs.
The patient burden, characterized by the higher prevalence of various
comorbidities was also substantial.
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Purpose: Erosive hand osteoarthritis (EOA) is considered a subset of hand
osteoarthritis (OA) affecting mainly the interphalangeal (IP) joints. Because
little is known about its etiology, we evaluated potential risk factors for the
evolution of EOA.
Methods: Hand radiographs of 236 hand OA patients (mean age 59 yrs, 83%
women) participating in the Genetics, ARthrosis and Progression (GARP)
study were obtained at baseline and after six years. Hand OA was deﬁned
by the ACR criteria for clinical hand OA or the presence of structural
abnormalities (nodes/radiographic OA). Evolution in anatomical phase of IP
joints according to the Verbruggen-Veys system was assessed by scoring
paired radiographs in chronological order. In every IP joint the presence of
self-reported pain and stiffness (using a diagram including all IP joints), the
presence of pain on joint pressure and the presence of nodes was evaluated
at baseline. In addition, osteophytes and joint space narrowing (JSN) were
scored using the OARSI atlas. At the patient level, pain and functional
limitations were assessed with the Australian/Canadian Osteoarthritis Hand
Index (AUSCAN). Baseline HsCRP levels and innate cytokine production
(interleukin (IL)-1β, IL-1β receptor antagonist, IL-10 and tumor necrosis
factor-α) were included to reﬂect systemic inﬂammation and its predis-
position. Risk factors for the evolution of non-EOA IP joints to EOA and
for the evolution of active erosions to remodeling were assessed using
Generalized Estimating Equations (GEE) to take into account intra-patient
correlation.
Results: At baseline and follow-up 203 (4.7%) and 315 (7.4%) respectively
of the 4232 IP joints were classiﬁed as EOA. Non-EOA was present in 1487
(35%) at baseline and 1530 (36%) IP joints at follow-up. The remaining IP
joints were classiﬁed as normal. Of the 1487 non-EOA IP joints at baseline
97 (6.5%) progressed to EOA. Clinical and radiographic risk factors for this
evolution are shown in the table. Of the 91 IP joints with active erosions
at baseline 69 (76%) became remodeled. The presence of self-reported pain
was an independent risk factor for this ongoing erosive evolution (OR
(95%CI) 3.52 (1.08, 11.46)). Systemic inﬂammation was not associated with
either of the processes.
Table 1. Association between evolution of non-EOA to EOA and baseline characteristics
OR (95% CI)* OR (95% CI)**
Joint level
Self-reported pain 3.87 (2.40, 6.22) 2.01 (1.12, 3.63)
Self-reported stiffness 2.65 (1.49, 4.71) 1.68 (0.83, 3.40)
Pain on pressure 3.70 (2.37, 5.77) 1.52 (0.87, 2.65)
Node 3.22 (1.85, 5.63) 1.76 (0.86, 3.59)
Osteophyte grade 2-3 1.20 (0.38, 3.72) –
JSN grade 2-3 15.32 (9.16, 25.61) 13.29 (7.81, 22.64)
Patient level
AUSCAN pain 1.10 (1.04, 1.17) 1.04 (0.93, 1.16)
AUSCAN function 1.06 (1.02, 1.09) 0.99 (0.93, 1.05)
*Adjusted for age, sex, BMI; **Adjusted for variables associated in ﬁrst analysis and for
age, sex, BMI.
Conclusions: JSN was an independent risk factor for the evolution to
EOA, implying that local processes involved in cartilage loss may play a
role in the development of EOA. Pain was an independent risk factor for
the evolution to EOA as well as for the ongoing erosive process, which
may suggest a role for local inﬂammation. Further investigation on these
premises in longitudinal ultrasound or MRI studies is needed.
